Merck & Co Inc (MRK)

neg -0.95
Today's Range: 53.00 - 54.11 | MRK Avg Daily Volume: 12,411,100
Last Update: 11/30/15 - 4:01 PM EST
Volume: 12,248,046
YTD Performance: -4.98%
Open: $54.04
Previous Close: $53.96
52 Week Range: $45.69 - $63.62
Oustanding Shares: 2,793,543,137
Market Cap: 150,069,137,320
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 7
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.00 2.00
Latest Dividend: 0.46
Latest Dividend Yield: 3.43%
Dividend Ex-Date: 12/11/15
Price Earnings Ratio: 14.44
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
14.44 14.40 32.68
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.80% -9.69% 22.97%
Revenue -4.10 -0.12 -0.04
Net Income 164.20 0.87 0.23
EPS 176.90 1.02 0.26
Earnings for MRK:
Revenue 42.24B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $0.90 $0.90 $3.56 $3.78
Number of Analysts 8 1 8 12
High Estimate $0.93 $0.90 $3.59 $4.01
Low Estimate $0.88 $0.90 $3.55 $3.57
Prior Year $0.87 $0.85 $3.49 $3.56
Growth Rate (Year over Year) 3.45% 5.88% 2.08% 6.11%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
There is more room on the upside, but resistance ahead could temper gains.
Gilead Sciences, Merck and Pfizer offer healthy prospects at attractive prices.

Thank God It's Friday! Real Money Pro($)

Good morning! Bret Jensen here.
Investors should ignore the temporary issues that have knocked the sector down.

Why Biotech Has Bottomed Real Money Pro($)

Investors should ignore the temporary issues that have knocked the sector down.
Three Action Alerts PLUS holding are set to report results.
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
Some smaller biotechs offer good value at current levels.

Columnist Conversations

JD also pops big last minute on very heavy volumes
Sudden rise in BaBa in last fifteen minutes on no news.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.